Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Insight Public Affairs

We are an award winning 15-strong team of consultants able to offer extensive experience in politics, government, media and stakeholder engagement, across a breadth of policy areas including telecoms, technology, gambling, life sciences, financial services, housing, infrastructure, copyright, employment, media and advertising, food and drink, social care, retail, and education. As an independent agency we go that extra mile to deliver results-focussed communications strategies and programmes that fulfil our clients’ commercial imperatives. Working tirelessly to meet our clients’ goals, we are a team who understand client challenges, develop bespoke strategies and programmes, and meet these strategic objectives.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

- PMLiVE

Visions4Health

Visions4Health are market access experts and your gateway to local adoption at pace. Leveraging our lived experience, understanding of national and local healthcare systems, and insights generated by our stakeholder…

View Profile

Health policy and government affairs, Market access, Market research

Company Details

Insight Public Affairs
52 Grosvenor Gardens, London, SW1W 0AU, United Kingdom
+44 (0)20 7824 1865
Contact Insight Public Affairs
Website

 Latest Content from PMHub 

Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report

White Papers and Resources | July 5, 2017 | Inizio

Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase...

Research Partnership is celebrating 20 years in business

White Papers and Resources | July 5, 2017 | Inizio

Watch our short video to see how we have grown. Please note the video comes with some fun, themed music. https://www.researchpartnership.com/news/2017/06/research-partnership-is-celebrating-20-years-in-bus...

Therapy Watch expands oncology and IBD portfolios

White Papers and Resources | July 5, 2017 | Inizio

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in...

Lucid Partners grows its medical writing team

Press Releases | June 30, 2017 | Lucid Group Communications Limited

The past year has been the most successful for Lucid Group yet. They have celebrated their 10th year of business, launched their new Strategic Consultancy, won a Queen’s Award for...

PEGASUS SHOWREEL 2017

Videos and Podcasts | June 26, 2017 | Inizio

The new pharma marketing playbook

White Papers and Resources | June 23, 2017 | An agency called Owen

Do you know about the 5 key areas that must be in your pharma marketing playbook?

Pharma needs to evolve from customer-centricity to stakeholder-centricity

White Papers and Resources | June 23, 2017 | An agency called Owen

Customer-centricity and patient-centricity is no longer enough for pharma sales and marketing strategies as digital promises better customer experiences for all pharma stakeholders.

How to plan, execute and refine an excellent congress experience

White Papers and Resources | June 22, 2017 | Blue Latitude Health

Medical congresses are one of the most important and intensive marketing activities a company can undertake. Here, Account Director Dolan Desai and Senior Creative Copywriter Dale Choate give you the...

How can pharma help the NHS capitalise on its data?

White Papers and Resources | June 21, 2017 | Wilmington Healthcare

Sue Thomas, Paul Midgley and Steve How, of Wilmington Healthcare, explain how pharma can work with the NHS to transform services

21st Century Cures Act: a commercial perspective on how the new FDA regulation could revolutionise use of RWE and analytics in healthcare

White Papers and Resources | June 20, 2017 | Blue Latitude Health

The 21st Century Cures Act has transformed the US drug development landscape. David Cooney explores the implications of the Act for pharmaceutical companies and reveals how it can be leveraged.